BioLineRx Ltd. Reports Q3 2024 Financial Results
Ticker: BLRX · Form: 6-K · Filed: Nov 25, 2024 · CIK: 1498403
Sentiment: neutral
Topics: financial-results, quarterly-report
TL;DR
BioLineRx dropped Q3 2024 earnings on 11/25 - check the numbers.
AI Summary
BioLineRx Ltd. announced its financial results for the three and nine months ended September 30, 2024, on November 25, 2024. The company also published its unaudited interim consolidated financial statements and an operating and financial review as of that date.
Why It Matters
This filing provides investors with the latest financial performance data for BioLineRx Ltd., crucial for understanding the company's current financial health and operational status.
Risk Assessment
Risk Level: low — This is a routine financial results filing and does not introduce new material risks.
Key Players & Entities
- BioLineRx Ltd. (company) — Registrant
- September 30, 2024 (date) — Reporting period end date
- November 25, 2024 (date) — Date of press release and filing
FAQ
What period do the financial results announced on November 25, 2024, cover?
The financial results announced on November 25, 2024, cover the three and nine months ended September 30, 2024.
What other documents were published along with the financial results?
Along with the financial results, the Registrant also published its unaudited interim consolidated financial statements and its operating and financial review.
Is BioLineRx Ltd. required to file annual reports under Form 20-F or Form 40-F?
Yes, BioLineRx Ltd. indicates it files annual reports under cover of Form 20-F.
What is the principal executive office address of BioLineRx Ltd.?
The principal executive office address of BioLineRx Ltd. is 2 HaMa’ayan Street, Modi’in 7177871, Israel.
When was the company's name last changed?
The company's name was last changed on August 5, 2010, from BioLineRX, Ltd. to BioLineRx Ltd.
Filing Stats: 285 words · 1 min read · ~1 pages · Grade level 13.7 · Accepted 2024-11-25 07:07:08
Filing Documents
- zk2432387.htm (6-K) — 9KB
- exhibit_1.htm (EX-99) — 369KB
- exhibit_2.htm (EX-99) — 473KB
- exhibit_3.htm (EX-99) — 264KB
- image00001.jpg (GRAPHIC) — 27KB
- image00003.jpg (GRAPHIC) — 59KB
- 0001178913-24-003823.txt ( ) — 1236KB
From the Filing
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant's name into English) 2 HaMa'ayan Street Modi'in 7177871, Israel (Address of Principal Executive Offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F Form 40-F On November 25, 2024, the Registrant issued a press release announcing its financial results for the three and nine months ended September 30, 2024. The Registrant is also publishing its unaudited interim consolidated financial statements, as well as its operating and financial review, as of September 30, 2024 and for the three and nine months then ended. Attached hereto are the following exhibits: Exhibit 1: Registrant's press release dated November 25, 2024; Exhibit 2: Registrant's condensed consolidated interim financial statements as of September 30, 2024 and for the three and nine months then ended; and Exhibit 3: Registrant's operating and financial review as of September 30, 2024 and for the three and nine months then ended. This Form 6-K, the text under the heading "Third Quarter 2024 Financial Results" in Exhibit 1, Exhibit 2 and Exhibit 3 are hereby incorporated by reference into all effective registration statements filed by the registrant under the Securities Act of 1933. Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BioLineRx Ltd. By: /s/ Philip A. Serlin Philip A. Serlin Chief Executive Officer Dated: November 25, 2024